2014
DOI: 10.1016/j.biomaterials.2014.05.067
|View full text |Cite
|
Sign up to set email alerts
|

Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
42
0

Year Published

2015
2015
2020
2020

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 57 publications
(46 citation statements)
references
References 52 publications
4
42
0
Order By: Relevance
“…This T H 1-biasing is primarily due to the pathway activated in binding of CpG ODN by TLR-9 in the endolysosome of antigen-presenting cells, 46 but is likely also enhanced by the PLGA nanoparticle delivery system, which enhances antigen uptake by antigen-presenting cells, 32 facilitates uptake of CpG ODN into the endolysosome, 47 and increases MHC I antigen presentation. 36 Overall, the vaccine containing both the CpG ODN immunomodulatory adjuvant and the PLGA nanoparticle delivery system was necessary to produce a robust Figure 4. Tc24-specific antibody response.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This T H 1-biasing is primarily due to the pathway activated in binding of CpG ODN by TLR-9 in the endolysosome of antigen-presenting cells, 46 but is likely also enhanced by the PLGA nanoparticle delivery system, which enhances antigen uptake by antigen-presenting cells, 32 facilitates uptake of CpG ODN into the endolysosome, 47 and increases MHC I antigen presentation. 36 Overall, the vaccine containing both the CpG ODN immunomodulatory adjuvant and the PLGA nanoparticle delivery system was necessary to produce a robust Figure 4. Tc24-specific antibody response.…”
Section: Discussionmentioning
confidence: 99%
“…23,[28][29][30] Nanoparticles have been shown to increase antigen uptake by antigen-presenting cells 31 and enhance the T H 1-mediated CD8 C T cell response [32][33][34] through increased MHC I antigen presentation. 35 Nanoparticles can also serve as a depot for antigen, 36 allowing prolonged stimulation of the T H 1 pathway. 37 A common polymer used in nanoparticle synthesis is poly(lactic-co-glycolic acid) (PLGA).…”
Section: Introductionmentioning
confidence: 99%
“…The results of this study gives applicable data for designing optimal vaccination regimens in MP-based protein vaccines. 102 However, it was found that polymer nature and MP characteristics are 2 affecting factors in the outcome of CpG and antigen co-encapsulating. For example, when OVA and CpG sequences were coencapsulated into Resomer Ò RG PLGA 502 and 756 MPs, no improvement in cellular immune response was seen in Table 6.…”
Section: Cpgmentioning
confidence: 99%
“…102,103 For example, 3 formulations including addition of CpG in soluble form, CpG adsorption on, and CpG encapsulation into PLGA MPs with the adsorbed protein antigen from Neisseriameningitidis B were evaluated. The results indicated that CpG encapsulated formulations led to increased immunopotentiator effect which was indicated by significant higher antibody, bactericidal activity and T cell responses when compared to the traditional method of delivering CpG in the soluble form.…”
Section: Cpgmentioning
confidence: 99%
“…One approach for studying in vivo release kinetics is to use non-invasive imaging with fluorescently-labeled antigens to assess vaccine depletion from controlled release depots over time. This technique has been used for one study, but has yet to be validated [191].…”
Section: Antigen Release Kineticsmentioning
confidence: 99%